Sufficiently important difference for common cold: severity reduction

Annals of Family Medicine

Volumn 5, Issue 3, 2007, Pages 216-223

  Barrett, Bruce ^a,d   Harahan, Brian ^a,b   Brown, David ^c   Zhang, Zhengjun ^a   Brown, Roger ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d University of Wisconsin   (United States)

Author keywords

Clinical significance; Common cold; Effect size; Evidence based medicine; Health policy research; Important difference; Outcomes; Quality of life; Quantitative methods; Questionnaires; Randomized clinical trial; Respiratory tract infections

Indexed keywords

ASCORBIC ACID; ECHINACEA EXTRACT; PLECONARIL; ZINC;

ADULT; AGED; ARTICLE; COMMON COLD; DISEASE SEVERITY; EDUCATION; ETHNICITY; FEMALE; HUMAN; INCOME; INTERVIEW; MAJOR CLINICAL STUDY; MALE; SMOKING;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; ASCORBIC ACID; COMMON COLD; ECHINACEA; FEMALE; HUMANS; MALE; MIDDLE AGED; OXADIAZOLES; PHYTOTHERAPY; PLANT EXTRACTS; QUESTIONNAIRES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VITAMINS; ZINC COMPOUNDS;

EID: 34249977849     PISSN: 15441709     EISSN: 15441717     Source Type: Journal    
DOI: 10.1370/afm.698     Document Type: Article

References (28)

1. Brand DA. Benefits, harms, and the design of clinical trials. Med Decis Making. 2005;25(3):246-247.
2. Guyatt GH, Osoba D, Wu AW, Wyrwich KW, Norman GR. Methods to explain the clinical significance of health status measures. Mayo Clin Proc. 2002;77(4):371-383.
3. Friedman L, Furberg C, DeMets D. Fundamentals of Clinical Trials. New York, NY: Springer-Verlag; 1998.
4. Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials. 1989;10(4):407-415.
5. Barrett B, Brown D, Mundt M, Brown R. Sufficiently important difference: expanding the framework of clinical significance. Med Decis Making. 2005;25(3):250-261.
6. Froehlich GW. What is the chance that this study is clinically significant? A proposal for Q values. Eff Clin Pract. 1999;2(5):234-239.
7. Herbert RD. How to estimate treatment effects from reports of clinical trials. I: Continuous outcomes. Aust J Physiother. 2000;46(3):229-235.
8. Schonstein E, Kenny D, Keating J, Koes B, Herbert RD. Physical conditioning programs for workers with back and neck pain: a cochrane systematic review. Spine. 2003;28(19):E391-E395.
9. Yelland MJ, Schluter PJ. Defining worthwhile and desired responses to treatment of chronic low back pain. Pain Med. 2006;7(1):38-45.
10. Barrett B, Brown R, Mundt M, et al. Using benefit harm tradeoffs to estimate sufficiently important difference: the case of the common cold. Med Decis Making. 2005;25(1):47-55.
11. Barrett B, Muller D, Rakel D, Rabago D, Marchand L, Scheder J. Placebo, meaning and health. Perspect Biol Med. 2006;49(2):178-198.
12. Barrett B, Brown R, Mundt M, et al. The Wisconsin Upper Respiratory Symptom Survey is responsive, reliable, and valid. J Clin Epidemiol. 2005;58(6):609-617.
13. Jackson GG, Dowling HF, Spiesman IG, Boand AV. Transmission of the common cold to volunteers under controlled conditions. I. The common cold as a clinical entity. AMA Arch Intern Med. 1958;101(2):267-278.
14. Jackson GG, Dowling HF, Anderson TO, Riff L, Saporta J, Turck M. Susceptibility and immunity to common upper respiratory viral infections - the common cold. Ann Intern Med. 1960;53:719-738.
15. Jackson GG, Dowling HF, Muldoon RL. Acute respiratory diseases of viral etiology. VII. Present concepts of the common cold. Am J Public Health. 1962;52:940-945.
16. Douglas RM, Hemila H, D'Souza R, Chalker EB, Treacy B. Vitamin C for preventing and treating the common cold. Cochrane Database Syst Rev. 2004;(4):CD000980.
17. Marshall I. Zinc for the common cold. Cochrane Database Syst Rev. 2000;(2):CD001364.
18. Melchart D, Linde K, Fischer P, Kaesmayr J. Echinacea for preventing and treating the common cold. Cochrane Database Syst Rev. 2000;(2):CD000530.
19. Hayden FG, Herrington DT, Coats TL, et al. Efficacy and safety of oral pleconaril for treatment of colds due to picornaviruses in adults: results of 2 double-blind, randomized, placebo-controlled trials. Clin Infect Dis. 2003;36(12):1523-1532.
20. Linde K, Barrett B, Wolkart K, Bauer R, Melchart D. Echinacea for preventing and treating the common cold. Cochrane Database Syst Rev. 2006;(1):CD000530.
21. Jefferson TO, Tyrrell D. Antivirals for the common cold. Cochrane Database Syst Rev. 2001;(3):CD002743.
22. Arroll B. Non-antibiotic treatments for upper-respiratory tract infections (common cold). Respir Med. 2005;99(12):1477-1484.
23. Kirsch I, Moore T, Scoboria A, Nicholls S. The emperor's new drugs: An analysis of antidepressant medication data submitted to the U.S. Food and Drug Administration. Prevention & Treatment. 2002;5:1-12.
24. Moncrieff J, Wessely S, Hardy R. Active placebos versus antidepressants for depression. Cochrane Database Syst Rev. 2004;(1):CD003012.
25. Walsh BT, Seidman SN, Sysko R, Gould M. Placebo response in studies of major depression: variable, substantial, and growing. JAMA. 2002;287(14):1840-1847.
26. Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP, van den Bussche H. Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials. BMJ. 2005;331(7512):321-327.
27. Lanctot KL, Herrmann N, Yau KK, et al. Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. CMAJ. 2003;169(6):557-564.
28. Trinh NH, Hoblyn J, Mohanty S, Yaffe K. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. JAMA. 2003;289(2):210-216.